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ABSTRACT Flavopiridol is a cyclin-dependent kinase (CDK) inhibitor that pro-
motes cell cycle arrest. We aimed to examine the anti-proliferative effects of the 
flavopiridol and oxaliplatin combination on p16INK4A deficient melanoma cells 
B16F10 and also its apoptotic effects on a subcutaneously injected B16F10 allograft 
melanoma tumor model. Flavopiridol and oxaliplatin treated B16F10 cell viability 
was determined by MTT assay. C57BL6 mice were injected with B16F10 cells and 
treated with flavopiridol after tumor implantation. BRAF and BCL2L1 mRNA expres-
sion levels were measured using reverse transcription-polymerase chain reaction 
(RT-PCR). Caspase 9 and caspase 3/7 activity were determined by activity assay kits. 
Proliferating cell nuclear antigen (PCNA) and B-cell lymphoma 2 (BCL-2) protein ex-
pression levels were analyzed immunohistochemically. Flavopiridol and oxaliplatin 
decreased cell death. Flavopiridol enhanced caspase 3/7 and caspase 9 activities 
in vitro and in vivo in a dose dependent manner via the mitochondrial apoptotic 
pathway. Even though there was a significant increase in Bcl-2 staining, PCNA stain-
ing was decreased in flavopiridol-administered mice. Decreased PCNA expression 
showed antiproliferative effects of flavopiridol which might be the result of cell-cy-
cle arrest. Flavopiridol can be used as a cell cycle inhibitor, which induced apoptosis 
through the mitochondrial pathway, independently from BCL2 in B16F10 cells and 
B16F10 injected C57BL6 allografts.
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INTRODUCTION
Malignant melanoma is a neoplasm of melano-
cytes and is considered a serious health problem due 
to both annual incidence and death rates (1). Malig-
nant melanoma can develop in any tissue involving 
melanocytes including the skin, eye, and mucosal ep-
ithelium of the internal ear. Patients with malignant 
melanoma who have high risk of developing meta-
static disease may benefit from adjuvant therapy. 
2
3There have been some agents developed to inhibit 
specific mutations in malignant melanoma cells. Un-
derstanding the role of these mutations and activa-
tion mechanisms has led to the identification of sur-
vival pathways and resistance mechanisms (2). 
BRAF is a member of the RAF kinase family of the 
serine/threonine kinases in the ERK/MAPK pathway. 
BRAF gene activating mutations (V600E and V600K) 
are found in approximately 50% of melanomas (3). 
The constitutive activation of BRAF kinase enhances 
the RAS–RAF–MEK–ERK pathway and thereby induc-
es melanoma cell survival and proliferation. Vemu-
rafenib is a mutant BRAF inhibitor drug that has been 
approved by the FDA (4). After vemurafenib, tramet-
enib (5), a MEK inhibitor and dabrafenib (6), a BRAF 
inhibitor, have been announced for use in treatment 
of malignant melanoma. KIT mutations have been 
another molecular change identified in many mela-
nomas. However, KIT inhibitors such as imatinib have 
not been useful in patients with activating mutations 
of the c-KIT gene (7).
Almost 10% of patients with malignant melanoma 
had a family history of the disease, which is linked to a 
genetic cause on the short arm of chromosome 9. The 
deleted locus on chromosome 9 hosts the CDKN2A 
gene, and the germ-line mutations of this gene has 
been associated with familial malignant melanomas 
(8,9). The CDKN2A locus has two overlapping genes, 
p14ARF and p16INK4a, which are entirely different 
tumor suppressor proteins (10,11). While p16INK4a 
regulates RB activation, p14ARF regulates the p53 
pathway. P16INK4a binds and inhibits the CyclinD/
CDK4/6 complex and thereby prevents RB phosphor-
ylation and causes G1/S cell cycle arrest (12). MDM2 
functions as a negative regulator of the cell cycle 
by ubiquitinating p53, which is a well-known tumor 
suppressor protein. p14ARF inactivates MDM2 and 
thus activates p53 (13). The loss of p16INK4a and/or 
p14ARF directly affects cell cycle control (14). 
Understanding cell cycle regulation and cell death 
will be beneficial for identifying the pathogenesis 
and the appropriate treatment of malignant mela-
noma. Programmed cell death, apoptosis, represents 
a complex signaling mechanism consisting of several 
intracellular and extracellular pathways. Binding of 
ligands to specific death receptors triggers the extra-
cellular pathway. This receptor-ligand interaction is 
followed by intracellular caspase cascade. The initia-
tor caspase 8 activates caspase 3 and 7 that induces 
endonucleases, resulting in DNA fragmentation (15). 
On the other hand, the intrinsic or mitochondrial 
pathway is triggered by the release of cytochrome-
c from mitochondria in response to several intracel-
lular disorganizations such as DNA damage, loss of 
mitochondrial transmembrane potential, increased 
oxidative stress, serum starvation, and activation of 
oncogenes (16). The mitochondrial translocation of 
pro-apoptotic Bcl-2 family members such as BAX, BID, 
and BAK proteins assists the release of cytochrome-c 
(17,18). When cytochrome-c is released into cytosol 
it forms an oligomeric complex with APAF-1 (apop-
tosome) (19,20). When the apoptosome complex is 
formed, it recruits the initiator pro-caspase 9. Acti-
vated caspase 9 induces caspase 3 and 7, which lead 
to DNA fragmentation (21). 
The Bcl-2 family of proteins has both pro- and anti-
apoptotic characteristics. While Bcl-2, Bcl-XL, Mcl-1, 
Bcl-W, and Bcl-2L10 proteins contain four BH domains 
and prevent cell apoptosis, Bim, Bid, Bad, Bik, Puma, 
and Noxa proteins induce apoptosis (22). Alternative 
splicing of Bcl-2L1 (Bcl-X) mRNA forms two function-
ally distinct mRNAs. Bcl-XL is the longest isoform and 
acts as an inhibitor of apoptosis. On the other hand, 
Bcl-XS is the shortest isoform, which binds and in-
hibits Bcl-2 and then inhibits survival. Bcl-XL directly 
binds and closes the VDAC mitochondrial channel 
where BAX and BAK allow cytochrome c transition to 
cytosol (23). 
Irregular CDK activity is frequently observed in 
malignant melanoma cells; thus, CDK inhibition is a 
rational approach to lead cell cycle arrest and then 
apoptosis (24,25). Flavopiridol is a semisynthetic fla-
vanoid obtained from Dysoxylum binectariferum (26). 
Flavopiridol is reported to inhibit in vitro cell growth 
through CDKs (CDK2, CDK4, CDK6) in G1/S or G2/M 
of the cell cycle (27,28). There have also been several 
studies showing flavopiridol`s apoptotic effects on 
melanoma cell lines (29). Combination studies of the 
flavopiridol and platin groups or other chemothera-
py agents also show preclinical and clinical effects in 
terms of inhibiting the cell cycle and triggering apop-
tosis (30-32).
Proliferating cell nuclear antigen (PCNA) is a slid-
ing clamp of DNA polymerase delta which catalyze 
DNA synthesis and take part in DNA repair (33). Thus, 
it is important to find PCNA decrease in order to get 
antiproliferative results of an applied agent.
The therapeutic advantage of DNA damaging 
agents relies on their ability to inhibit the cell cycle 
and enhance apoptosis in tumor tissue. It is thus im-
portant to evaluate the proliferative and apoptotic 
response against antineoplastic agents in vitro and 
in vivo. In this study, we aimed to examine the anti-
proliferative effects of the flavopiridol and oxaliplatin 
combination on the p16INK4A deficient melanoma 
cell line B16F10 and also its apoptotic effects on an 
allograft tumor model as a single agent.
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MATERIALS AND METHODS
Cell lines and cell culture
The murine melanoma cell line B16F10 was ob-
tained from American Type Culture Collection. Cells 
were maintained in the Dulbecco’s modified Eagle 
(DMEM) medium supplemented with 10% heat-inac-
tivated fetal bovine serum, 100 U/mL penicillin and 
100 μg/mL streptomycin (all from Hyclone, USA). Cells 
were grown in a humidified incubator containing 5% 
CO2 and 95% air at 37°C. B16F10 cells do not express 
p16INK4A and p14ARF genes. 
Reagents
Flavopiridol was obtained from Enzo (USA). A 10 
mg/mL stock solution was prepared in dimethyl sulf-
oxide (DMSO). Oxaliplatin was purchased from Tocris 
(USA). A 86.33 mg/mL stock solution was prepared in 
DMSO.
Animal studies
Eight weeks old C57BL6 mice weighing 25 g were 
purchased from the Laboratory of Animal Breeding 
and Experimental Research Center of Gazi University. 
Local Institutional Committee for the Ethical Use of 
Animals of Gazi University approved experimental 
procedures. Animals were fed with standard diet and 
water. C57BL6 mice received an injection of 5×106 
B16F10 cells in 200 mL phosphate-buffered saline 
(PBS) subcutaneously. Twenty-four C57BL6 mice bear-
ing B16F10 tumors were separated into four groups, 
six mice per group. Groups received intraperitoneal 
injections of DMSO, 2.5 mg/kg, 5.0 mg/kg and 10.0 
mg/kg of flavopiridol at day 12 and 15 after tumor 
implantation. Mice from the control and flavopiridol 
groups were sacrificed by cervical dislocation after 
the last day of drug application. Tumor tissues were 
retrieved for analysis. 
Cell viability
Cell viability was determined by MTT assay. Cells 
were seeded in DMEM at 7×103 cells/200 μL per well 
in 96 well plates for 24h at 37°C. When cells were at-
tached after 24 h, cells were treated with DMSO (con-
trol group), only flavopiridol (50 nM; 100 nM; 200 
nM; 400 nM), only oxaliplatin (40 μM; 80 μM) and a 
combination of flavopiridol and oxaliplatin for 24 and 
48 hours. After incubation time, a 10 μL MTT solution 
(0.5 mg/mL) was added to each well. After 4h of MTT 
incubation at 37°C, a 100 μL crystal dissolving buffer 
was added and the plates were gently shaken on an 
orbital shaker for 5 min. The absorbance at 570 nM 
was measured with a microplate reader. Each treat-
ment was repeated four times. The mean absorbance 
of four wells was used as an indicator of relative cell 
growth.
RNA extraction and cDNA synthesis
3×106 B16F10 cells were seeded in 6 well plates 
and incubated with DMSO (control group) and flavo-
piridol (50 nM; 100 nM; 200 nM) for 24 and 48 hours.
B16F10 injected C57BL6 mice also received 2.5, 5.0 
and 10.0 mg/kg flavopiridol and sacrificed. In vitro 
total RNA was extracted with the “High Pure RNA 
Isolation kit” (Roche, Germany) protocol. In vivo total 
RNA was extracted from subcutaneous tumors (ap-
proximately 50-100 mg) using the Trizol reagent. The 
RNA-containing pellet was treated with 1-5 U RNase-
free DNase per μg RNA and incubated at 37°C for 30 
min before washing with 75% ethanol. The amount 
and quality of the RNA of each sample were deter-
mined by measuring the absorbance at 260 and 280 
nm using the Nanodrop spectrophotometer (Nano-
Drop ND-1000, NanoDrop Technologies, USA). Total 
RNA (1 μg) was reverse transcribed in a 20-μL reaction 
mixture using random hexamers and the Transcriptor 
First-Strand cDNA Synthesis kit (Roche, Germany) ac-
cording to manufacturer instructions. cDNA was used 
as a template for real time quantitative PCR analysis. 
Quantitative real-time polymerase chain 
reaction PCR (reverse transcription (RT)-
PCR) analysis
BRAF and BCL2L1 mRNA expression levels were 
measured using RT-PCR with the LightCycler 480 
(Roche, Germany). β-actin (ACTB) was used as a 
housekeeping gene in order to normalize BRAF and 
BCL2L1 expression levels. Probes and primers span-
ning exon-exon boundaries for each gene assay were 
designed using the Universal Probe Library (UPL). 
Primer and UPL probe numbers are presented in Table 
1. The reaction mixture was prepared in 96 well plates 
containing 1 X LightCycler Taq-Man Master reaction 
mixture. Each sample was tested three times. 
Caspase 9 protein activity
2×106 cells were seeded in 6 well plates and incu-
bated with DMSO (control group) and flavopiridol (50 
nM and 100 nM) for 24 and 48 hours. B16F10 injected 
C57BL6 mice also received 2.5, 5.0, and 10.0 mg/kg 
flavopiridol and sacrificed the next day after the last 
injection. After sacrificing, tumors were stored at 
-80°C for protein activity assays. Protein concentra-
tion of each sample was determined using the BCA 
kit (Thermo, USA). Caspase 9 protein activity of each 
sample was measured by the “Caspase 9 Colorimetric 
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Assay Kit” (BioVision, Palo Alto, CA) according to the 
kit protocol. 
Caspase 3/7 protein activity
2×106 cells were seeded in 6 well plates and incu-
bated with DMSO (control group) and flavopiridol (50 
nM and 100 nM) for 24 and 48 hours. B16F10 injected 
C57BL6 mice also received 2.5, 5.0, and 10.0 mg/kg 
flavopiridol and sacrificed the next day after the last 
injection. After sacrificing, tumors were stored at -
80°C for protein activity assays. Protein concentration 
of each sample was determined using the BCA kit 
(Thermo, USA). Caspase 3/7 protein activity was mea-
sured using the “Anaspec Sensolyte Homogeneous 
AFC Kaspaz 3/7 Assay Kit” (Anaspec, USA), according 
to the assay protocol. 
Immunohistochemistry
After the animals were sacrificed their tumors 
were excised, fixed in formalin, and embedded in 
paraffin for immunohistochemical staining. Paraffin 
sections were rehydrated in a series of xylene and 
ethanol washes. Antigen retrieval was carried out 
using a preheated target retrieval solution (pH 6.0) 
(Dako, Carpinteria, CA, USA). For immunohistochem-
istry, Vectastain Elite ABC kits (Vector Laboratories) 
were used according to manufacturer’s instructions 
for blocking, dilution of primary antibody, and label-
ing. Sections were incubated with primary antibody 
against PCNA (Abbomax, #500-2854) and Bcl-2 (Dako, 
#102230) overnight at 4°C. 3.3-diaminobenzidine was 
prepared fresh from tablets (Sigma-Aldrich). Positive 
cells for each antibody of all mice from each group 
were counted using microscopy with estimation of 
intensity of staining (<10 weak, 11-50% medium, and 
51-80% strong).
Figure 1. a) The proliferation inhibitory effects of flavopiridol on B16F10 cells followed by the MTT assay. Viability rates of 
flavopiridol were shown in a time- and dose-dependent manner. B16F10 cells were treated with 50, 100, 200, and 400 nM 
of flavopiridol for 24 and 48 hours. *P<0.05 
b) The proliferation inhibitory effects of oxaliplatin on B16F10 cells followed by the MTT assay. Viability rates of oxaliplatin 
were shown in a time- and dose-dependent manner. B16F10 cells were treated with 40 and 80 µM of oxaliplatin for 24 and 
48 hours. *P<0.05 
c) The proliferation inhibitory effects of the flavopiridol and 40 µM oxaliplatin combination on B16F10 cells followed by 
the MTT assay. Viability rates after flavopiridol and oxaliplatin administration were shown in a time- and dose-dependent 
manner. *P<0.05 Dimethyl sulfoxide (DMSO) versus treated group or combination; πP<0.05 Combination versus flavopiridol 
treated group. 
d) The proliferation inhibitory effects of the flavopiridol and 80 µM oxaliplatin combination on B16F10 cells followed by the 
MTT assay. Viability rates after flavopiridol and oxaliplatin administration were shown in a time- and dose-dependent man-
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Statistical analysis
Differences in cytotoxicity, immunohistochemi-
cal staining values, and protein activity levels were 
analyzed using SigmaStat software (version 12.0) 
by using the Student`s t-test and one-way analysis 
of variance (ANOVA). P<0.05 were considered sig-
nificant. Statistical significance of differences in BRAF 
and BCL2L1 mRNA expression levels was analyzed by 
the relative expression software tool (REST) designed 
for group-wise comparison and statistical analysis of 
relative expression results. 
RESULTS
B16F10 cell proliferation was significantly de-
creased at 100, 200, and 400 nM concentrations of 
flavopiridol at 24 and 48 hours. IC50 (Inhibition Con-
centration) value of flavopiridol was determined as 
100 nM at 24 hour incubation (Figure 1, a). Oxaliplatin 
inhibited B16F10 cell proliferation at the concentra-
tions of 40 and 80 μM at 24 and 48 hours (Figure 1, b). 
However, the combination of flavopiridol and oxali-
platin did not have as much antiproliferative effects 
as single agents alone (Figure 1, c and d). After the 
ineffective combination results, we chose to apply 
flavopiridol as a single agent in all following experi-
ments. 
In vivo and in vitro BCL2L1 and BRAF relative mRNA 
expression levels did not differ significantly between 
the control and flavopiridol groups (Figure 2, a and b). 
Although in vitro BCL2L1 and BRAF mRNA expression 
levels were decreased with flavopiridol treatment, 
the difference was not statistically significant (Figure 
2, a). 
When B16F10 cells were treated with 50 and 100 
nM of flavopiridol for 6, 24, and 48 hours, caspase 
9 protein activity had a tendency to increase in all 
groups. Caspase 9 activity was significantly increased 
at 50 nM concentration at 6, 24, and 48 hours. Also, 
100 nM of flavopiridol increased caspase 9 protein ac-
tivity significantly at 24 hours (Figure 3, a). However, 
caspase 3/7 protein activity was generally decreased 
Table 1. Primer sequences and probe numbers
Gene Forward primer Reverse primer UPL Probe No.
ACTB CTAAGGCCAACCGTGAAAAG ACCAGAGGCATACAGGGACA 64
BRAF GCTGGGACACGGACATTT GCAAAAGTCACAAAATGCTAAGG 55
BCL2L1 GTACCTGAACCGGCATCTG GGGGCCATATAGTTCCACAA 75
Figure 2. 
a) In vitro relative mRNA expressions of BCL2L1 and BRAF 
comparing control and flavopiridol treated groups. Bars 
represent mRNA expression normalized with β-actin 
(ACTB); P<0.05. 
b) In vivo relative mRNA expressions of BCL2L1 and BRAF 
comparing control and flavopiridol treated groups. Bars 
represent mRNA expression normalized with ACTB; P<0.05.
2. a) 2. a)
2. b)
Gokce et al. Acta Dermatovenerol Croat
Flavopiridol in malignant melanoma   2016;24(1):2-12
ACTA DERMATOVENEROLOGICA CROATICA
at 50 nM flavopiridol concentration at all hours. On 
the other hand, 100 nM of flavopiridol increased cas-
pase 3/7 activity significantly at 24 and 48 hours (Fig-
ure 3, b). 
When C57BL6 mice were injected with B16F10 
cells, tumors were formed after 7 days. Flavopiridol 
was applied two times intraperitoneally at the con-
centrations of 2.5, 5.0, and 10.0 mg/kg. All RNA and 
protein analysis was done from the same tissues. In 
vivo caspase 9 protein activity was significantly in-
creased at 2.5 and 5.0 mg/kg of flavopiridol concen-
trations (Figure 3, c). At the same time, caspase 3/7 
activity was significantly increased at 5.0 and 10.0 
mg/kg flavopiridol (Figure 3, d). 
Interestingly, we did not observe a decrease at 
Bcl-2 staining with flavopiridol treatment upon im-
munohistochemical analysis (Figure 4, a and b). Bcl-
2 was significantly increased with flavopiridol treat-
ment in each treatment group. However, PCNA levels 
significantly decreased in coordination with caspase 
levels in the flavopiridol treated groups (Figure 4, c 
and d). This data was also correlated with decreased 
in vitro proliferation rates.
DISCUSSION
Malignant melanoma has 10-year survival rates 
less than 10% and has been difficult to treat for cli-
nicians (1). However, several molecular approaches 
have helped understand the biology of malignant 
melanoma and lead to progress in treatment strate-
gies. Driver BRAF and MEK gene mutations are the 
most famous molecular targets. To date, vemurafenib 
and dabrafenib (mutant BRAF inhibitors), (34) tra-
metinib (MEK1/2 inhibitor) (35), and their combina-
tions (36) have been used and approved by the FDA 
for metastatic malignant melanoma. However, resis-
tance mechanisms such as the alternative pathway 
or CDK4/6 activations affect response rates even for 
combination therapies (37). The small molecule in-
hibitors those target the antiapoptotic BCL2 family 
members or IAPs are important to understand the 
apoptosis resistance mechanisms. Although mela-
noma cells are generally insensitive to these single 
agents, combination therapies have yielded promis-
ing results (38). CTLA-4, PD-1, and PDL-1 targets have 
also been tried in clinical trials (39,40) with promis-
ing results as combination therapies (41). Thus, even 
though new molecular targets and their inhibitors 
have been determined, blocking the cell cycle is still a 
rational option for inhibiting tumor cell proliferation.
Flavopiridol, the first approved CDK inhibitor, has 
been shown to mimic p16, which is frequently lost 
or mutated in malignant melanoma. In this study, 
Figure 3. a) Increased in vitro caspase 9 protein activity in 
B16F10 cells in a time- and dose-dependent manner after 
flavopiridol administration. *P<0.05 
b) In vitro caspase 3/7 protein activity in B16F10 cells in a 
time- and dose-dependent manner after flavopiridol ad-
ministration. *P<0.05 
c) Increased in vivo caspase 9 protein activity of B16F10 
allograft tumors in C57BL6 mice after flavopiridol treatment. 
*P<0.05 
d) In vivo caspase 3/7 protein activity of B16F10 allograft 
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we investigated the effects of flavopiridol at various 
concentrations in anti-proliferative and apoptotic 
events and gene expression profiles in a p16 deficient 
B16F10 mouse melanoma cell line and an allograft 
tumor model in C57BL6 mice. In our study, IC50 value 
was determined as 100 nM for 24 hours in flavopiridol 
applied B16F10 cells. In agreement with our study, 
Robinson et al. reported that cell cycle was inhibited 
even for low doses of flavopiridol (12.5 nM – 25.0 nM) 
and caused apoptosis at 100 nM. Although higher 
concentrations decreased IC50 concentration they did 
not affect expression of anti-apoptotic BCL2 expres-
sion (29). Jackman et al. showed flavopiridol induced 
cell cycle arrest and apoptosis at lower concentra-
tions. However, reduced CDK activity was observed 
at higher flavopiridol doses in acute lymphoblastic 
leukemia cells (42). 
The antiproliferative effect of flavopiridol has 
been shown to increase when applied with various 
agents in clinical and preclinical studies (30-32). In 
our study, oxaliplatin decreased proliferation at 80 
µM (IC50 concentration) at 48 hours. However, combi-
nation of flavopiridol and oxaliplatin did not have as 
much antiproliferative effects as single agents alone. 
In a phase I study, a flavopiridol and oxaliplatin/fluo-
rouracil (5-FU)/folinic acid combination was safe and 
tolerable for advanced solid tumors (31). 
The apoptosis mechanism triggered by flavopiri-
Figure 4. a) Quantification of immunohistochemistry for in vivo B-cell lymphoma 2 (BCL-2) protein expression of B16F10 
allograft tumors in C57BL6 mice after flavopiridol treatment. Columns represent mean percentage of tumor cells with posi-
tive staining. *P<005 
b) Representative images of immunohistochemistry for BCL-2 staining of B16F10 allograft tumors in C57BL6 mice after 
dimethyl sulfoxide (DMSO) (a), 2.5 mg/kg flavopiridol (b), 5.0 mg/kg flavopiridol (c), and 10.0 mg/kg flavopiridol treatment 
(×200) 
c) Quantification of immunohistochemistry for in vivo proliferating cell nuclear antigen (PCNA) protein expression of 
B16F10 allograft tumors in C57BL6 mice after flavopiridol treatment. Columns represent mean percentage of tumor cells 
with positive staining. *P<0.05 
d) Representative images of immunohistochemistry for PCNA staining of B16F10 allograft tumors in C57BL6 mice after 
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dol has still not been well-established. It has however 
been shown that it may be BCL2 dependent or inde-
pendent. Ma et al. showed flavopiridol treatment can 
enhance apoptosis through stabilizing E2F1 and tran-
scriptionally repressing MCL-1 in H1299 lung carcino-
ma cells (43). Lucas et al. also showed lower doses of 
flavopiridol increased apoptotic NOXA protein levels 
and sensitizes MM200 and Me4405 melanoma cells 
to ABT-737, a BH-3 mimetic agent in 2D and 3D cul-
tures [44). According to our findings, BCL2L1 mRNA 
expression did not change significantly in control and 
flavopiridol treated groups in both in vitro and in vivo 
studies. We also did not observe any decrease in BCL2 
protein levels in flavopiridol treated allograft tumors. 
In agreement with our study, it has been shown that 
flavopiridol induced apoptosis independently from 
BCL2 expression (45). On the other hand, flavopiridol 
has downregulated BCL2 mRNA and protein expres-
sion and induced apoptosis within 24 hours in B cell 
leukemia cell lines (46). It has been shown that BCL2 
expression was induced by flavopiridol in leukemic 
blasts in adult acute leukemia patients (47). The stud-
ies examining flavopiridol’s apoptotic effects do not 
clearly explain the role of BCL2 protein expression in 
apoptosis. Although Konig et al., Sato et al., and New-
comb et al. showed BCL2 decreased as a result of the 
apoptotic effects of flavopiridol in different cell lines, 
we could not find any difference between flavopiridol 
treated and untreated groups in our study (46,48,49). 
In line with our study, flavopiridol induced apoptosis 
through caspase 3 activation independently from 
BCL2 or p53 function in chronic lymphocytic leuke-
mia cells (50).  
It is also known that flavopiridol can induce apop-
tosis through caspase-dependent or independent 
mechanisms according to the mutational status and 
histologic type of the cell. In our study, flavopiridol 
induced caspase 9 activation both in vivo and in vitro. 
Also, caspase 3/7 was upregulated at higher doses of 
flavopiridol in the cells and tumor model. In glioma 
cell lines, flavopiridol did not activate caspase 3, poly 
ADP ribose polymerase (PARP), or caspase 8 indepen-
dently from tumor suppressor pathway changes such 
as retinoblastoma and p53. Mitochondrial damage 
and cytochrome c release were also not observed in 
those cells (47). However, Li et al. showed flavopiridol 
caused the release of cytochrome c from mitochon-
dria, activated caspase 9, 8, and 3, increased proapop-
totic BAX, and decreased BCL2 protein levels in drug 
resistant osteosarcoma and Ewing’s family tumor 
cells (51). Additionally, Puppo et al. determined that 
flavopiridol increased caspase 3 activation, however 
it had no effect in stimulating caspase 9 and led to 
apoptosis through mitochondrial pathway activation 
in neuroblastoma cells (52). G2 arrest and cyclin B1 
downregulation were also observed in low concen-
trations of flavopiridol application in rhabdoid cells. 
When flavopiridol was combined with 4OH-tamoxifen 
it did not affect flavopiridol induced G2 arrest but led 
to caspase-3/7 activation. p53 inhibition by siRNA re-
moved flavopiridol-induced G2 arrest but enhanced 
apoptosis by activating caspase 2 and 3 (53). 
On the other hand, Mahoney et al. have shown 
that flavopiridol protects chronic lymphocytic leuke-
mia cells from autophagy, which causes resistance to 
cyclin-dependent kinase targeted therapies [(54,55)]. 
However, Xiao et al. showed a HSP90 inhibitor 17-
AAG can sensitize mantle cell lymphoma cells to fla-
vopiridol induced authophagy and also enhanced 
apoptosis (56).  Immunochemical evaluation of PCNA 
protein expression is one of the methods used to de-
termine cellular proliferation level in tumor tissue. 
PCNA is synthesized in the S phase of cell cycle that is 
an indicator of DNA synthesis; it is important in deter-
mining mitosis number and mitotic index (57). Verda-
guer et al. observed decreased PCNA expression and 
apoptosis after flavopiridol application in primary 
cultures of rat cerebellar granule cells (58). In our in 
vivo study, the decrease in PCNA protein expression 
and increase in caspase 3/7 and caspase 9 activities 
may show that flavopiridol stopped the cell cycle and 
led to apoptosis through the mitochondrial pathway. 
CONCLUSION
Apoptosis was induced by flavopiridol indepen-
dently from BCL2L1 through the mitochondrial path-
way in which caspase 3/7 and caspase 9 activated in 
p16INK4A and p14ARF mutant cell line B16F10 and 
B16F10 injected C57BL6 mice. PCNA expression was 
decreased by flavopiridol, which caused cell cycle 
arrest in the melanoma model. Nonetheless, while 
there are still many mechanisms and unclear results 
to investigate, flavopiridol can be used as a cell cycle 
inhibitor and apoptosis inducer in malignant mela-
noma. 
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